• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

High phosphorylated cyclin-dependent kinase 2 expression indicates poor prognosis of luminal androgen receptor triple-negative breast cancer.

作者信息

Jin Zining, Zhang Qingfu, Wang Chunyu, Wang Shengli, Lin Lin, Zou Renlong, Sun Ge, Zeng Kai, Zhou Baosheng, Tong Yuxin, Chen Bo, Zhao Yue

机构信息

Department of Cell Biology, Key laboratory of Cell Biology, Ministry of Public Health, and Key laboratory of Medical Cell Biology, Ministry of Education, School of Life Sciences, China Medical University, Shenyang 110122, China.

Department of Breast Surgery, the First Hospital of China Medical University, Shenyang 110001, China.

出版信息

Acta Biochim Biophys Sin (Shanghai). 2022 Jul 25;54(7):1034-1038. doi: 10.3724/abbs.2022083.

DOI:10.3724/abbs.2022083
PMID:35838199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9827805/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/face/9827805/0cfa392d6532/ABBS-2022-031-t2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/face/9827805/a77caa2a3f10/ABBS-2022-031-t1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/face/9827805/0cfa392d6532/ABBS-2022-031-t2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/face/9827805/a77caa2a3f10/ABBS-2022-031-t1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/face/9827805/0cfa392d6532/ABBS-2022-031-t2.jpg

相似文献

1
High phosphorylated cyclin-dependent kinase 2 expression indicates poor prognosis of luminal androgen receptor triple-negative breast cancer.高磷酸化细胞周期蛋白依赖性激酶2表达提示腔面雄激素受体三阴性乳腺癌预后不良。
Acta Biochim Biophys Sin (Shanghai). 2022 Jul 25;54(7):1034-1038. doi: 10.3724/abbs.2022083.
2
Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.雄激素受体和 FOXA1 的共表达定义了一种“腔面雄激素受体”的猫乳腺肿瘤亚型，这是乳腺癌的自发模型。
BMC Cancer. 2019 Dec 30;19(1):1267. doi: 10.1186/s12885-019-6483-6.
3
Editorial: The Androgen Receptor in Breast Cancer.社论：乳腺癌中的雄激素受体
Front Endocrinol (Lausanne). 2021 Jan 15;11:636480. doi: 10.3389/fendo.2020.636480. eCollection 2020.
4
Tackling the diversity of triple-negative breast cancer.攻克三阴性乳腺癌的异质性。
Clin Cancer Res. 2013 Dec 1;19(23):6380-8. doi: 10.1158/1078-0432.CCR-13-0915.
5
Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.三阴性乳腺癌中的雄激素受体生物学：关于分类为雄激素受体阳性（AR+）或四阴性疾病的依据
Horm Cancer. 2015 Dec;6(5-6):206-13. doi: 10.1007/s12672-015-0232-3. Epub 2015 Jul 23.
6
IPH-926 lobular breast cancer cells are triple-negative but their microarray profile uncovers a luminal subtype.IPH-926 乳腺癌细胞为三阴性，但它们的基因芯片分析结果揭示了一个腔面亚型。
Cancer Sci. 2013 Dec;104(12):1726-30. doi: 10.1111/cas.12276.
7
Androgen Receptor and ALDH1 Expression Among Internationally Diverse Patient Populations.国际不同患者群体中的雄激素受体和醛脱氢酶1表达
J Glob Oncol. 2018 Oct;4:1-8. doi: 10.1200/JGO.18.00056.
8
Histological Features and Tissue Microarray Taxonomy of Nigerian Breast Cancer Reveal Predominance of the High-Grade Triple-Negative Phenotype.尼日利亚乳腺癌的组织学特征和组织芯片分类显示高级别三阴性表型占主导地位。
Pathobiology. 2016;83(1):24-32. doi: 10.1159/000441949. Epub 2016 Jan 6.
9
Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinoma.癌症相关成纤维细胞来源的细胞因子对雌激素受体阴性乳腺癌中雄激素合成酶的影响。
Breast Cancer Res Treat. 2017 Dec;166(3):709-723. doi: 10.1007/s10549-017-4464-5. Epub 2017 Aug 22.
10
A Machine Learning Approach to Differentiate Two Specific Breast Cancer Subtypes Using Androgen Receptor Pathway Genes.基于雄激素受体通路基因的机器学习方法对两种特定乳腺癌亚型的鉴别。
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211027900. doi: 10.1177/15330338211027900.

引用本文的文献

1
FUNDC2, a mitochondrial outer membrane protein, mediates triple-negative breast cancer progression via the AKT/GSK3β/GLI1 pathway.FUNDC2，一种线粒体外膜蛋白，通过 AKT/GSK3β/GLI1 通路介导三阴性乳腺癌的进展。
Acta Biochim Biophys Sin (Shanghai). 2023 Nov 25;55(11):1770-1783. doi: 10.3724/abbs.2023142.

本文引用的文献

1
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.分子亚型分类和基因组分析在难治性转移性三阴性乳腺癌的精准医学中扩展：FUTURE 试验。
Cell Res. 2021 Feb;31(2):178-186. doi: 10.1038/s41422-020-0375-9. Epub 2020 Jul 27.
2
Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.三阴性乳腺癌的免疫组化分子分型：分子基础与临床相关性。
Oncologist. 2020 Oct;25(10):e1481-e1491. doi: 10.1634/theoncologist.2019-0982. Epub 2020 Jun 1.
3
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
三阴性乳腺癌的基因组和转录组全景：亚型和治疗策略。
Cancer Cell. 2019 Mar 18;35(3):428-440.e5. doi: 10.1016/j.ccell.2019.02.001. Epub 2019 Mar 7.
4
CDK4/6 inhibition in breast cancer: current practice and future directions.乳腺癌中的CDK4/6抑制：当前实践与未来方向
Ther Adv Med Oncol. 2018 Jul 17;10:1758835918786451. doi: 10.1177/1758835918786451. eCollection 2018.
5
Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification.根据 Lehmann 改良分类，接受新辅助卡铂和多西他赛治疗的三阴性乳腺癌队列的病理反应。
Clin Cancer Res. 2018 Apr 15;24(8):1845-1852. doi: 10.1158/1078-0432.CCR-17-1912. Epub 2018 Jan 29.
6
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.单细胞动力学决定三阴性乳腺癌对 CDK4/6 抑制的反应。
Clin Cancer Res. 2017 Sep 15;23(18):5561-5572. doi: 10.1158/1078-0432.CCR-17-0369. Epub 2017 Jun 12.
7
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.全激酶组RNA干扰筛选揭示了PDK1在雌激素受体阳性乳腺癌对CDK4/6抑制的获得性耐药中的作用。
Cancer Res. 2017 May 1;77(9):2488-2499. doi: 10.1158/0008-5472.CAN-16-2653. Epub 2017 Mar 1.
8
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.7 种三阴性乳腺癌分子亚型对新辅助化疗的差异性反应。
Clin Cancer Res. 2013 Oct 1;19(19):5533-40. doi: 10.1158/1078-0432.CCR-13-0799. Epub 2013 Aug 15.
9
X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.X-tile：一种用于生物标志物评估和基于结果的切点优化的新型生物信息学工具。
Clin Cancer Res. 2004 Nov 1;10(21):7252-9. doi: 10.1158/1078-0432.CCR-04-0713.